Unity provides Phase 1 study data for UBX1325
February 14th 2022During a presentation at the Bascom Palmer Eye Institute Angiogenesis, Exudation, and Degeneration 2022 conference, Robert Bhisitkul, MD, PhD, provided 24-week clinical data from the Phase 1 study, demonstrating that patients with DME and wAMD showed improved visual acuity through 24 weeks following a single dose of UBX1325.
Read More
FDA approves generic version of cyclosporine ophthalmic emulsion as dry eye treatment
February 4th 2022The FDA has approved the first generic of cyclosporine ophthalmic emulsion (Restasis; Allergan) 0.05% single-use vials of eye drops to increase tear production in patients with dry eye disease.
Read More
Heidelberg Engineering supporting Glaucoma/Myopia OCT Phenotyping Consortium
February 1st 2022The GMOPC was established in February 2020 at an inaugural meeting in Los Angeles, California, as an investigator-initiated clinical research study, with Heidelberg Engineering as an industry partner.
Read More